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Technical note: Evaluation of three
autoanalysers for use in chemical pathology
E. M. Nareborf
Central Laboratory & Blood Bank, PO Box 59082, Riyadh 11525, Kingdom of
Saudi Arabia
Three autoanalysers, the EPOS 5060, ERIS 6170 and the
Analyst, were evaluatedfor their adequacyfor use in laboratories
attached to Saudi ’polyclinics’. All the analysers showed compar-
able within-batch imprecision. The Analyst was found to be the
most useful because it was simple and practical and because its
throughput time was faster than the other two analysers. The
EPOS 5060 would be more suitablefor screening large numbers of
samplesfor single parameters; and the ERIS 6170 essentially suits
normal routine chemical laboratory work.
Materials and methods
Instruments
EPOS 5060 analyser
This is a bench-top batch analyser.Samples (5-25 tl per
test) are loaded via a chain link for assay. Being a batch
analyser, reagents are changed manually for each
parameter to be assayed, and require between 25-100 1
per test. Reagents of different brands can be utilized
without modification (it is an open system). The approxi-
mate cost was about 350 000 Saudi Riyals (SR) for the
instrument and between 0-05-2" 14 SR per test.
Introduction
A number of ’polyclinics’ with clinical laboratories were
set up in many parts of the Kingdom of Saudi Arabia by
the Government in 1984 (these ’polyclinics’ are similar in
concept to the UK’s Health Centres). In th Riyadh
health region alone, 80 of the 120 such government-
owned ’polyclinics’ have clinical laboratories. There are
also as many private ’polyclinics’ with laboratories in the
Riyadh region.
In these ’polyclinics’, chemical pathology tests were to be
performed with autoanalysers, the results of which were
to be reliable and comparable to those produced by the
larger hospital laboratories in major cities. An analyser
that would suit these ’polyclinics’ should be durable;
show good, consistent imprecision and accuracy; provide
a reasonably quick turn-round time; and should require a
very short training period.
The Central Laboratory and Blood Bank in the Central
Hospital in Riyadh is a large laboratory. Between 1984
and 1986, various biochemical autoanalysers were evalu-
ated by the Biochemistry Department at the Central
Laboratory and Blood Bank. Amongst these were the
EPOS 5060, ERIS 6170 (both sold by Eppendorf
Geratebau, FR Germany); and the Analyst (Du Pont,
USA). Comprehensive studies of the EPOS 5060 and
ERIS 6170 have already been published [1, 2]. Only
those features of interest to this study are discussed here.
So far, no independent study of the Analyst has been
published.
The purpose of this study was to determine the adequacy
of these autoanalysers for use in ’polyclinics’ in Saudi
Arabia.
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ERIS 6170 analyser
The ERIS 6170 is a multichannel, discrete analyser of
about the same size (1010 x 740 x 1090 mm) and
technology as the Hitachi 705 (Boehringer Mannheim
GmbH), the autoanalyser in current use in the depart-
ment for daily routine work. Samples are introduced for
assay via a chain link, which is similar to the Epos.
However, unlike the Epos, any combination of multiple
choice of test assays on any one patient’s sample can be
analysed. It is also an open system, but during this study
reagents from E. Merck (Darmstadt, FR Germany),
which were supplied by the agent were used. A built-in
computerized quality-control scheme facility is available,
however this was not tested nor was it utilized rigorously
during this study. The cost price of the instrument was
about 600 000 SR and between 0"04-1"40 SR per test.
The Analyst
This is a bench-top, compact, sophisticated multichannel
discrete profiler analyser. It measures about 216 x 635 x
330 mm and weighs about 19 kg. Reagents are supplied
by Du Pont in prepacked disc rotors, which also contain
the reaction cuvettes. At the time of this study, the
following disc rotors were available.
(a) A 12 chem rotor, lot No. 6K1019-12; for the assay
of glucose, urea, creatinine, uric acid, cholesterol,
calcium, triglycerides, total bilirubin, aspartate
transaminase, alanine transaminase, alkaline
phosphatase and gamma glutamyl transferase,
respectively.
(b) A 7 chem rotor, lot No. 565-7; for assaying glucose,
urea, creatinine, uric acid, aspartate transaminase,
alanine transaminase and cholesterol, respectively.
(c) A 3 chem rotor, lot No. 6B1005-3; for glucose,
urea, and creatinine assays respectively.
(d) A chem rotor, lot No. 6J1006G-1; for glucose
assays.
0142-0453/90 $3.00 1990 Taylor & Francis Ltd. 189E. M. Narebor Technical note
All chem rotors used in this study still had at least 9
months’ shelf-life before their recommended expiry dates.
It is a completely closed system with respect to reagent
utility. However, it requires only 90 btl of serum for the
assay of all the parameters in the 12 chem rotor. The
Analyst does not require daily calibration like most other
multichannel discrete autoanalysers. It also has a built-in
quality-control system, but this facility was neither tested
nor used rigorously during this study. The Analyst costs
about 40 000 SR and approximately 1-2"5 SR per test.
Quality control
Throughout this study two sets of quality-control (QC)
assessment schemes were maintained. One set was
physiological and pathological internal (QC) sera sup-
Table l(a). Mean accuracy values compared with Biotrol
(commercial internal quality control serum). N 50.
Biotrol EPOS ERIS Analyst
Glucose 5"3 5"2 5.0 5"3
(mmol/1) 2 11"4 11"2 11"6 11.4
3 8"8 8"4 8"6 8"6
Urea 5"7 5-6 5"4 5"8
(mmol/1) 2 15"5 15"6 15"0 15"3
3 10"7 10"0 10"5 10"6
Creatinine 90"9 89"0 90"0 91 "0
(txmol/1 2 563"6 564"0 562-0 563"0
3 327"3 325"8 326"0 327"4
AST (U/l) 12"0 11"0 12"0 12"0
2 81-0 83"0 80"6 80"8
3 46"8 47"0 45"9 46"3
ALT (U/l) 11"0 11"0 11"0 11"0
2 80-0 80"0 79"4 80"0
3 46"2 45"4 46"0 47"0
Alkaline 35"0 34"6 35.4 35"0
phosphatase 2 92’0 91’6 91.4 92’2
(bt/1 3 65"0 66"0 63"0 64’ 7
1, physiological level; 2, pathological level; 3, mixture of 500
of and 500 xl of 2 [3].
plied by Biotol (rue de Foin, Paris, France), and the other
set was supplied by the manufacturers’ agents (E. Merck,
Darmstadt, FR Germany; Du Pont, Biomedical Product
Department, Wilmington, USA). Alternating physio-
logical and pathological QC sera from our internal set
and the agents’ set were assayed at the beginning and end
ofeach batch. The QC sera were also assayed at random
intervals amongst test samples in within-batch analyses.
The coefficient of variation of these quality-control sera
are shown in table 3.
Analytical
Evaluation of each analyser laSted for between six and
eight weeks. Analytical methods used are shown in table
l(b). Each analyser had built-in thermostat control
device for assays that required incubation at 37C.
Accuracy of results were studied using the department’s
internal quality control sera (Biotol, rue de Foin, Paris,
France). Imprecision was assessed with the same internal
quality control sera in duplicate at the beginning and end
of each batch, and at irregular intervals between test
patients’ within-batch samples. A third QC serum was
made by mixing equal aliquots of the internal QC sera
[3]; this was assayed in a similar way. The theoretical
value ofthis third QC serum was calculated from the sum
of the physiological and pathological sera divided by two
(see table l[a]) (Biotol, rue de Foin, Paris, France).
The effect of high concentrations of bilirubin and lipids
were evaluated using highly icteric and turbid samples
chosen randomly from patients’ specimens. The through-
put time of each analyser was studied by taking the
average time to assay, in triplicate, 12 identical para-
meters.
Two technicians with different levels of experience in
clinical laboratory work (about 3 months and over 2
years, respectively) were shown how to operate each
analyser. They were then each given 50 randomly chosen
samples to assay for glucose, urea, creatinine, AST, ALT
and alkaline phosphatase on each analyser on 2 consecu-
tive days.
Table 1 (b). Analytical methods used during this study.
Hitachi
705
EPOS
5060
ERIS
6170 Analyst
Glucose Hexokinase/
G-6P-DH[6]
Gluc/
DH
Gluc/ Hexokinase/
DH G-6P-DH[6]
Urea Urease/
GLDH
--DO-- --DO-- --DO--[7]
Creatinine Jaff6 kinetic DO-- --DO-- Creatinine
amidohydrolase[8]
AST Aspartate
ALT Alanine
NAD+[9] AST/MDH[10]
NAD+ [9] pH 7.8
Alkaline pNPP[ 11
phosphatase
pNPP[11] pNPP[11] pNPP[12]
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Table 2. Comparison of imprecision using Biotrol quality control
serum (N-- 50).
Analyte Hitachi EPOS ERIS Analyst
Glucose (mmol/1)
Mean 5"3 5"2 5"2 5"3
SD 0"53 0"52 0"52 0"53
% CV 2"65 2"65 2"65 2"63
Urea (mmol/1)
Mean 5"4 5-6 5"6 5"8
SD 0"53 0"54 0"54 0"55
% CV 2"65 2" 70 2"70 2"72
Creatinine (tmol/1)
Mcan 90 91 90 91
SD 2"18 2"19 2"18 2"19
% CV 10-90 10-95 10.90 10.95
AST (U/l)
Mean 11 "0 12"0 13"0 12"0
SD 0"75 0"79 0"83 0"79
% CV 3.80 3.95 4.15 3-95
ALT (U/l)
Mean 11"0 11"0 12-0 11"0
SD 0"76 0"76 0"79 0"76
% CV 3"80 3"80 3"95 3"80
Alkaline phosphatase (U/l)
Mean 33"4 33"0 34"0 33"0
SD 1-33 1"32 1"33 1-32
Table 3. Coefficient of within-batch variation.
Analyte
Biotrol Merck Du Pont
Int. QC Qc Qc
(Hitachi) (ERIS) (Analyst)
Glucose N 0"7 0"9 0"8
P 0"8 0"9 0"8
Urea N 1"9 1"8 1"7
P 0"7 0"9 0-8
Creatinine N 1" 1"2 1-2
P 1"2 1"2 1"2
AST N 0"7 0"9 0"8
P 2"1 2"5 2"2
ALT N "5 "8 1.4
P 3"6 3"2 3"3
ALP N 2"5 2"4 2"6
P 2"6 2"3 2"6
N, physiological; P, pathological.
Correlation studies
Fifty randomly selected test patient samples from the
daily pool were assayed simultaneously on each analyser,
and on the Hitachi 705, for glucose, urea, creatinine,
AST, ALT and alkaline phosphatase in triplicate for 5
consecutive weeks. The cumulative average value for
each parameter from each analyser was calculated.
Aliquots of six samples from the ERIS 6170 study kept at
about -20C for around three weeks were thawed and
assayed for creatinine only on the Analyst.
Scatter diagrams of correlations using the calculated
cumulative average values, were plotted between the
Hitachi 705 and ERIS 6170, Hitachi 705 and Analyst and
ERIS 6170 and Analyst, respectively, for the parameters
indicated. The correlation coefficients (and regression
lines) were calculated according to Swinscow [4].
Results
Table l(a) shows the variation in the mean accuracy
values quoted for the quality control (Biotrol) sera for the
parameters indicated between the three autoanalysers
tested. On the basis of these results, accuracy can be
classified as good. Imprecision was also, on average,
satisfactory, see table 2. The dynamic throughput times
are given in table 6. Although the times observed during
this study are slightly longer than the manufacturers’
claims, they are quite satisfactory.
Correlation scatter plots between the Hitachi 705 and
ERIS 6170 and Hitachi 705 and Analyst are shown in
figure 1; and those between the ERIS 6170 and Analyst in
figure 2 for the parameters indicated. The corresponding
calculated correlation coefficients are shown in tables 4
and 5. Good linear positive correlations were observed for
the parameters indicated. The correlation observed for
creatinine between the ERIS 6170 and the Analyst is
interesting since the study was not carried out simul-
taneously on the same day, as were those between the
Hitachi 705 and ERIS 6170, and Hitachi 705 and
Analyst.
Table 4. Correlation resultsfrom the Hitachi 705 compared with those of the Analyst ,and ERIS 6170 (N 50).
Intercept Correlation coeff. Standard error
Slope (y)’ (r) (t) P
A E A E A E A E A E
Glucose 1.0 0.9 19(1.9) 27(2"1) 0.99 0"89 0.004 0.004 0-001
Creatinine 0"9 1"0 0"19(0"1) 0"2(0"14) 0"99 0"98 0"004 0"004 0"001
Urea 1"5 1"3 15(3"4) 19(2"7) 0"98 0"98 0"004 0"004 0"001
AST 1"0 1.0 2 x (1.8) 3 x (1-9) 0’99 0"98 0"004 0"004 0"001
ALP 0"9 0"9 10 x (6) 9 x (7) 0"99 0"99 0"004 0"004 0-001
ALT 1"3 1-3 3(3) 4(3) 1"05 1"03 0"004 0-004 0"001
Units as in tables l(a) and 2; P, Probability distribution of [7]; A, Analyst; and E, ERIS 6170.
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Figure 1 (a). Scatter diagram to show the correlation between the Hitachi 705 and the Analyst, and the Hitachi 705 and the ERIS 6170.
N= 50.
Table 5. Correlation resultsfrom the ERIS compared with those
from the Analystfor creatinine.
Correlation Standard
Intercept coefficient error
Slope ’)"I" (r) (t) P
1-0 0" 1"0 0"003 0"01
Units as in tables and 2; P, distribution of [7].
Table 6. Dynamic throughput times: number ofanalysesper hour.
Discussion
All the analysers evaluated in this study require sep-
arated serum for analyses. Both the EPOS 5060 and
ERIS 6170 can be modified to carry out other non-routine
t.ests. The Analyst, on the other hand, can only assay for
those tests indicated in any one chem disc rotor provided
by the manufacturer. All three analysers are much more
economical in terms of the sample and reagent volumes
required per test, than are many other analysers such as
the ACA III (a second autoanalyser now used for stat and
drug analyses in the department), which requires about
150 tl of serum per test.
Manufacturer’s This study
claim results
EPOS 300 270
ERIS 400 360
Analyst 55 50
A preprogrammable sample dilution facility is available
with the POS 5060. This facility was very useful in
making 1:10 and or 1:20 dilutions for samples which
indicated over the linear assay limits, and for imprecision
and accuracy studies. A similar facility was not available
for either of the other two analysers.
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Figure 1 (b). Scatter diagram to show the correlation between the Hitachi 705 and the Analyst; and the Hitachi 705 and the ERIS 6170.
N= 50.
Imprecision, on the whole, was best in the Analyst, even
with highly icteric and lipaemic samples. In general,
imprecision was observed to be very consistent in all three
analysers. The within-batch imprecision values, shown in
table 2, are satisfactory for the three analysers.
The overall performance of the three analysers was quite
satisfactory. Practically, the Analyst, a bench-top ana-
lyser would be preferred in Saudi’s ’polyclinics’ and in
small paediatric laboratories. The Analyst is compact,
portable and much easier to operate, than either of the
other two analysers. The suitability of the Analyst for the
UK’s National Health Service Health Centres has also
been discussed in Mires Magazine [5] (the Health Centres
are similar to the ’polyclinics’).
The EPOS 5060 would be suitable for hospital labora-
tories which serve daily disease-related clinics, for
example diabetic clinics. The ERIS 6170, on the other
hand, is a reliable analyser that could prove invaluable in
any large routine clinical chemical laboratory.
ERIS
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Figure 2. Scatter diagram to show the correlation between the
ERIS 6170 and the Analyst.
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